Industry reports
Editor highlights

Pathology

Summary

Table of Contents

Data Series

  • Publication date: April 2013
  • Report size: 66 pages
Keywords : cancer, musculoskeletal disorder, Autoimmune disease, endocrine disease, Insulin, obesity

Eli Lilly and Company (Lilly) is a pharmaceutical company, which is principally engaged in the design, development, manufacture, and selling of pharmaceutical products by utilizing up-to-date technological tools. It also conducts research to discover products to treat disease in animals. The company owns over 130 subsidiaries operating throughout the world. Lilly’s product portfolio includes Neuroscience products, Endocrinology products...

More »

Search ReportLinker

The Largest Collection of Market Research Reports

» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides

From +200,000 authoritative sources

Global Pathology Industry : Latest Reports

Trypanosomiasis - Pipeline Review, H2 2013

Trypanosomiasis - Pipeline Review, H2 2013

  • $ 2 000
  • Company report
  • December 2013
  • by Global Markets Direct

Trypanosomiasis - Pipeline Review, H2 2013 Summary Global Markets Direct's, 'Trypanosomiasis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides ...

Chronic Urticaria Or Hives - Pipeline Review, H2 2013

Chronic Urticaria Or Hives - Pipeline Review, H2 2013

  • $ 2 000
  • Company report
  • December 2013
  • by Global Markets Direct

Chronic Urticaria Or Hives - Pipeline Review, H2 2013 Summary Global Markets Direct's, 'Chronic Urticaria Or Hives - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. ...

Hemoglobinopathies - Pipeline Review, H2 2013

Hemoglobinopathies - Pipeline Review, H2 2013

  • $ 2 000
  • Company report
  • December 2013
  • by Global Markets Direct

Hemoglobinopathies - Pipeline Review, H2 2013 Summary Global Markets Direct's, 'Hemoglobinopathies - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report ...

Rubella - Pipeline Review, H2 2013

December 2013 $ 2 000

Global Pathology Industry : Latest Downloads

Company Report: Pathology for Year 2014

  • Company report
  • April 2014
  • 7 pages

Company Report: Pathology for Year 2014

  • Company report
  • April 2014
  • 6 pages

... For ampyra in stroke, the adaptive design of the phase 2/3 trial should allow acorda to take an interim look at efficacy as measured by 2-min walk distance as well as a scaled efficacy measurement similar ...


ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.